Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼ö¾Æ¼¼Æ÷Á¾ÀÇ ¼ö¼ú ÈÄ ¿ÜºÎ ¹æ»ç¼±Ä¡·á Postoperative External Beam Radiotherapy for Medulloblastoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 2È£ p.101 ~ 106
ÀüÇÏÁ¤, À̸íÀÚ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀüÇÏÁ¤ (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

À̸íÀÚ (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

Abstract

¸ñÀû : ¼ö¾Æ¼¼Æ÷Á¾¿¡ ´ëÇÑ ¼ö¼ú ÈÄ µÎ°³Ã´¼ö ¹æ»ç¼±Á¾¾çÇÐ ÀÇÇпë¾îÁý¿¡ µû¶ó ¹æ»ç¼±Ä¡·á
ÀÇ È¿°ú¸¦ Æò°¡ÇÏ°í ÃÖÀûÀÇ ¹æ»ç¼±Ä¡·á ¹æ¹ýÀ» ¾Ë¾Æº¸°íÀÚ ÇÔÀÌ º» ¿¬±¸ÀÇ ¸ñÀûÀÌ´Ù.
´ë»ó ¹× ¹æ¹ý : 1984³â 5¿ùºÎÅÍ 1998³â 4¿ù±îÁö º»¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ µÎ°³Ã´¼ö ¿ÜºÎ ¹æ
»ç¼±Ä¡·á¸¦ ¹ÞÀº 43¸íÀÇ ¼ö¾Æ¼¼Æ÷Á¾ ȯÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ÃßÀû±â°£Àº 18°³¿ù¿¡¼­
86°³¿ùÀ̾úÀ¸¸ç Áß¾ÓÃßÀû±â°£Àº 47°³¿ùÀ̾ú´Ù. ³²ÀÚ´Â 27¸íÀ̾ú°í ¿©ÀÚ 16¸íÀ¸·Î ¿ÏÀüÀý¼¼
¼ú, ³ª¸ÓÁö 24¸íÀÇ È¯ÀÚ¿¡¼­´Â ¾ÆÀýÁ¦¼úÀ» ½ÃÇàÇÏ¿´´Ù. ¸ðµç ȯÀÚ´Â µÎ °³Ã´¼ö ¹æ»ç¼±Ä¡·á¸¦
¹Þ¾Ò°í, 39¸íÀÇ È¯ÀÚ´Â ÃÖ¼Ò 5,000cGyÀÇ ¹æ»ç¼±À» ¿ø¹ßºÎÀ§¿¡ Á¶»ç¹Þ¾ÒÀ¸¸ç 40¸íÀÇ È¯ÀÚ´Â
ÃÖ¼Ò 3,000cGyÀÇ ¹æ»ç¼±À» ô¼ö¿¡ Á¶»ç¹Þ¾Ò´Ù.
°á°ú : ´ë»óȯÀÚ 43¸íÀÇ 5³â ¹× 7³â »ýÁ¸À²Àº 67% ¹× 56%À̾ú°í, 5³â ¹× 7³â ¹«º´»ýÁ¸À²
Àº °¢°¢ 60% ¹× 51%À̾ú´Ù. ¿ø¹ßº´¼ÒÀÇ ±¹¼ÒÁ¦¾îÀ²Àº 5³â ¹× 7³â¿¡ °¢°¢ 77% ¹× 67%À̾ú
´Ù. À°¾ÈÀü ¿ÏÀüÀýÁ¦¼ú ¹× ¾ÆÀý¼¼¼úÀ» ½ÃÇà¹ÞÀº ȯÀÚÀÇ 5³â »ýÁ¸À²Àº °¢°¢ 76% ¹× 66%ÀÌ
¾úÀ¸¸ç ¹Ý¸é¿¡ Á¶Á÷°Ë»ç¸¸À» ½ÃÇà¹ÞÀº ȯÀÚ´Â 5³â »ýÁ¸À²ÀÌ 40%¿¡ ºÒ°úÇÏ¿´´Ù. ÃÑ 18¸íÀÇ
Àç¹ßȯÀÚ Áß 11¸í¿¡¼­ ¿ø¹ßºÎÀ§°¡ Àç¹ßºÎÀ§À̾úÀ¸¸ç 7¸íÀÇ È¯ÀÚ´Â ¿ø¹ßº´¼Ò¿¡¼­¸¸ Àç¹ßÇÏ¿´
´Ù. 4¸íÀÇ È¯Àڴ ô¼ö¿¡¼­, 3¸íÀÇ È¯ÀÚ´Â ¿ø°ÝÀüÀ̸¸À» º¸¿´°í ³ª¸ÓÁö 4¸íÀº È­ÀÚ¿¡¼­ ¿ø¹ß
ºÎÀ§¸¦ Æ÷ÇÔÇÏ¿© ¿©·¯ºÎÀ§¿¡¼­ Àç¹ßÇÏ´Â ¾ç»óÀ» ³ªÅ¸³»¾ú´Ù.
°á·Ð : ¼ö¾Æ¼¼Æ÷Á¾ÀÇ ³úôÃß ¹æ»ç¼±Ä¡·á´Â À¯ÀÇÇÑ Ä¡·á ºÎÀÛ¿ëÀÌ ¾ø´Â È¿°úÀûÀÎ Ä¡·á¿ä¹ý
À̾ú´Ù. ±×·¯³ª ¿ø¹ßºÎÀ§ÀÇ ±¹¼ÒÄ¡·áÈ¿°ú¸¦ ³ôÀ̱â À§ÇÏ¿© °³¼±ÇÏ¿©¾ß ÇÒ Á¡ÀÌ ÀÖ´Â °ÍÀ¸·Î
»ç·áµÇ¸ç ÀÌ´Â ´ÙºÐÇÒ Á¶»ç, Á¤À§Àû ¹æ»ç¼±¼ö¼ú ¹× »ïÂ÷¿ø ÀÔü Á¶ÇüÄ¡·á µî ¹æ»ç¼±¿ä¹ýÀÌ
±â¼úÀû ¹ßÀüÀ¸·Î ÀÌ·ç¾î Áú ¼ö ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose : This study was performed to evaluate the effectiveness and tolerance of
craniospinal irradiation for patients with medulloblastoma and to define the optimal
radiotherapeutic regimen.
Materials and Methods : We retrospectively analyzed the records of 43 patients with
medulloblastoma who were treated with external beam craniospinal radiotherapy at our
institution between May, 1984 and April, 1998. Median follow up period was 47 months
with range of 18 to 86 months. Twenty seven patients were male and sixteen patients
were female, a male to female ratio of 1.7:1. Surgery consisted of biopsy alone in 5
patients, subtotal excision in 24 patients, and gross total excision in 14 patients. All of
the patients were treated with craniospinal irradiation. All of the patients except four
received at least 5,000 cGy to the posterior fossa and forty patients received more than
3,000 cGy to the spinal cord.
Results : The overall survival rates at 5 and 7 years for entire group of patients were
67% and 56%, respectively. Corresponding disease free survival rates were 60% and
51%, respectively. The rates of disease control in the posterior fossa were 77% and 67%
at 5 and 7 years. Gross total excision and subtotal excision resulted in 5 year survival
rate of 76% and 66%, respectively. In contrast, those patients who had biopsy alone had
a 5 year overall survival rate of only 40%. Posterior fossa was component of failure in
11 of the 18 recurrences. Seven recurrences were isolated to the posterior fossa. Four
patients had neuraxis recurrences, three had multiple sites of failure, and involving the
primary site.
Conclusion : Craniospinal irradiation for patients with medulloblastoma is an effective
adjuvant treatment without significant treatment related toxicities. There is room for
improvement in terms of posterior fossa control, especially in biopsy alone patients. The
advances in radiotherapy including hyperfractionation, stereotactic radiosurgery and 3D
conformal radiotherapy would be evolved to improve the tumor control rate at primary
site.

Å°¿öµå

¼ö¾Æ¼¼Æ÷Á¾; ¹æ»ç¼±Ä¡·á; Medulloblastoma; Radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS